Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder.from Moneycontrol Business News https://ift.tt/huFDQwR
Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder.
Comments
Post a Comment